-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga·03/17/2025 17:05:53
Listen to the news

Gainers

  • vTv Therapeutics (NASDAQ:VTVT) shares increased by 65.2% to $24.53 during Monday's regular session. The market value of their outstanding shares is at $64.0 million.
  • Monogram Technologies (NASDAQ:MGRM) stock increased by 52.35% to $3.55. The company's market cap stands at $121.8 million. As per the news, the Q4 earnings report came out 3 days ago.
  • Regencell Bioscience (NASDAQ:RGC) stock rose 46.67% to $18.51. The market value of their outstanding shares is at $240.8 million.
  • Scienture Holdings (NASDAQ:SCNX) stock moved upwards by 42.95% to $2.13. The company's market cap stands at $18.3 million.
  • Hyperfine (NASDAQ:HYPR) shares increased by 34.92% to $1.24. The market value of their outstanding shares is at $96.0 million. As per the news, the Q4 earnings report came out today.
  • CervoMed (NASDAQ:CRVO) shares moved upwards by 28.11% to $8.25. The company's market cap stands at $68.1 million. As per the press release, Q4 earnings came out today.

Losers

  • Revelation Biosciences (NASDAQ:REVB) stock declined by 19.7% to $2.73 during Monday's regular session. The market value of their outstanding shares is at $2.4 million.
  • bioAffinity Technologies (NASDAQ:BIAF) stock declined by 17.93% to $0.3. The market value of their outstanding shares is at $4.6 million.
  • Palisade Bio (NASDAQ:PALI) stock decreased by 14.88% to $0.85. The company's market cap stands at $2.5 million.
  • Plus Therapeutics (NASDAQ:PSTV) stock decreased by 12.7% to $0.59. The market value of their outstanding shares is at $3.4 million.
  • NRX Pharmaceuticals (NASDAQ:NRXP) shares declined by 12.56% to $2.06. The market value of their outstanding shares is at $34.7 million. The company's, Q4 earnings came out today.
  • GRI Bio (NASDAQ:GRI) stock declined by 12.14% to $5.26. The company's market cap stands at $2.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.